It‘s a deal!
The DEAL consortium and Elsevier conclude Germany-wide Open Access agreement
"This agreement will bring about a fundamental transformation in the scientific publishing landscape and enhance access to research findings from Germany," the representatives stated at a joint press conference on Wednesday. This five-year agreement will allow authors affiliated with participating institutions, including the Max Planck Society, to publish their research outcomes as open-access articles under an open license in Elsevier's journals, which include prominent brands like Cell Press and The Lancet. In addition to this new publishing opportunity, participating institutions will gain extensive reading access to virtually the entire portfolio of Elsevier journals on ScienceDirect.
The DEAL Consortium, representing the German research institutions, and Elsevier, a global leader in scientific information and data analytics, have entered into a five-year agreement. This agreement, signed on September 1 by Elsevier and the DEAL entity, MPDL Services gGmbH (MPDLS), is set to run until the end of 2028 and is designed to make a large part of German research openly accessible worldwide.
This agreement supports the transition to Open Access in Germany, enabling researchers to publish open access and read content across Elsevier’s extensive portfolio of high quality and trusted scientific journals including leading brands such as Cell Press and The Lancet.
Under this arrangement, authors affiliated with participating institutions, such as the Max Planck Society, can publish their articles in Elsevier's journals with immediate open access, with the publication fees being charged to their institution on a per-article basis. In addition, institutions will receive discounts on the list prices for their researchers' publications in fully open access Elsevier journals. Participating institutions will also have reading access to virtually the entire portfolio of Elsevier journals on ScienceDirect, the world’s largest platform dedicated to peer-reviewed primary scientific and medical research.
The Max Planck Digital Library (MPDL) organises participation in DEAL for the entire Max Planck Society. "The agreement reflects our shared vision for an open and affordable system of scholarly communication that maximises the impact of research, providing DEAL institutions with cost-effective open access publishing and reading services, and we are delighted to support them in implementing the agreement to extend these benefits to scholars and scientists across the German research landscape, “said Frank Sander, Managing Director of MPDLS.